Literature DB >> 30684870

A comprehensive review of salinomycin derivatives as potent anticancer and anti-CSCs agents.

Michał Antoszczak1.   

Abstract

Polyether ionophore antibiotics (ionophores) represent a large group of more than 120 lipid-soluble compounds that are widely used in veterinary medicine because of their significant antimicrobial activity. In addition to the industrial use of ionophores, some of them effectively and selectively inhibit properties of different cancer cells and enhance the antitumor effects of chemo- and/or radiotherapy. Salinomycin (SAL) is particularly interesting in this regard as it shows potent activity against various types of cancer cells, including those that display multi-drug resistance, and cancer stem cells. Therefore, a very interesting direction of research is chemical modification of SAL which may lead to obtaining analogs that are characterized by better biological activity and lower toxicity than those of the starting compound. This review article is focused on the possible role of both SAL-based drug delivery systems and SAL derivatives in future cancer therapy.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anticancer drugs design; Chemoselectivity; Dimerization; Drug-delivery systems; O-acylation; Reductive amination; Regioselectivity; Salinomycin; Semi-synthetic analogs; ‘Click’ chemistry

Mesh:

Substances:

Year:  2019        PMID: 30684870     DOI: 10.1016/j.ejmech.2019.01.034

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  9 in total

1.  Secondary Metabolites and Biosynthetic Gene Clusters Analysis of Deep-Sea Hydrothermal Vent-Derived Streptomyces sp. SCSIO ZS0520.

Authors:  Huaran Zhang; Yingying Chen; Yanqing Li; Yongxiang Song; Junying Ma; Jianhua Ju
Journal:  Mar Drugs       Date:  2022-06-14       Impact factor: 6.085

2.  Expeditive Synthesis of Potent C20-epi-Amino Derivatives of Salinomycin against Cancer Stem-Like Cells.

Authors:  Dominika Czerwonka; Sebastian Müller; Tatiana Cañeque; Ludovic Colombeau; Adam Huczyński; Michał Antoszczak; Raphaël Rodriguez
Journal:  ACS Org Inorg Au       Date:  2022-01-05

Review 3.  Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.

Authors:  Jimin Xu; Yu Xue; Richard Zhou; Pei-Yong Shi; Hongmin Li; Jia Zhou
Journal:  Med Res Rev       Date:  2020-12-05       Impact factor: 12.944

Review 4.  Emerging agents that target signaling pathways in cancer stem cells.

Authors:  Yue Yang; Xiaoman Li; Ting Wang; Qianqian Guo; Tao Xi; Lufeng Zheng
Journal:  J Hematol Oncol       Date:  2020-05-26       Impact factor: 17.388

5.  Synthesis and Anticancer Activity of Dimeric Polyether Ionophores.

Authors:  Michał Sulik; Ewa Maj; Joanna Wietrzyk; Adam Huczyński; Michał Antoszczak
Journal:  Biomolecules       Date:  2020-07-12

6.  A novel 3D polycaprolactone high-throughput system for evaluation of toxicity in normoxia and hypoxia.

Authors:  Atena Malakpour-Permlid; Stina Oredsson
Journal:  Toxicol Rep       Date:  2021-03-20

Review 7.  Salinomycin as a potent anticancer stem cell agent: State of the art and future directions.

Authors:  Dan Qi; Yunyi Liu; Juan Li; Jason H Huang; Xiaoxiao Hu; Erxi Wu
Journal:  Med Res Rev       Date:  2021-11-16       Impact factor: 12.388

Review 8.  Evidence of Metallic and Polyether Ionophores as Potent Therapeutic Drug Candidate in Cancer Management.

Authors:  Pratibha Pandey; Fahad Khan; Huda A Qari; Tarun Kumar Upadhyay; Abdulhameed F Alkhateeb; Mohammad Oves
Journal:  Molecules       Date:  2022-07-23       Impact factor: 4.927

9.  Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models.

Authors:  Alicja Urbaniak; Megan R Reed; Daniel Fil; Anika Moorjani; Sarah Heflin; Michał Antoszczak; Michał Sulik; Adam Huczyński; Michalina Kupsik; Robert L Eoff; Melanie C MacNicol; Timothy C Chambers; Angus M MacNicol
Journal:  Biomed Pharmacother       Date:  2021-06-12       Impact factor: 7.419

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.